Stephen Hawser1, Nimmi Kothari2, Noëlle Jemmely3, Nowel Redder3. 1. IHMA Europe Sàrl, Monthey, Switzerland. Electronic address: shawser@ihmainc.com. 2. IHMA Europe Sàrl, Monthey, Switzerland. 3. Correvio International Sàrl, Geneva, Switzerland.
Abstract
BACKGROUND: Ceftobiprole is approved for use in treatment of hospital-associated and community-acquired pneumonia in 17 different European countries and is currently undergoing clinical trials in the USA. METHODS: Isolates were collected from hospital laboratories from 15 European countries during 2018 as part of an ongoing post-marketing surveillance study. MICs were determined using EUCAST broth microdilution methodology and interpreted using 2019 EUCAST breakpoints. RESULTS: Ceftobiprole was active (MIC, ≤2 mg/L) against 100% and 98.9% of methicillin-susceptible Staphylococcus aureus and MRSA from 2018. Only six MRSA isolates (1.1%) were resistant to ceftobiprole and originated from four countries. Against S. pneumoniae, ceftobiprole was active (MIC, ≤0.5 mg/L) against 98.7% of isolates. Overall, 75.6% of Enterobacterales were susceptible though isolate numbers in certain countries were notably low. In addition, based on non-species related PK/PD breakpoints, 63.2% of Pseudomonas aeruginosa isolates were susceptible to ceftobiprole. CONCLUSIONS: The data for ceftobiprole for isolates from 2018 are very similar to studies performed on isolates from earlier years showing that susceptibility to ceftobiprole has remained high.
BACKGROUND:Ceftobiprole is approved for use in treatment of hospital-associated and community-acquired pneumonia in 17 different European countries and is currently undergoing clinical trials in the USA. METHODS: Isolates were collected from hospital laboratories from 15 European countries during 2018 as part of an ongoing post-marketing surveillance study. MICs were determined using EUCAST broth microdilution methodology and interpreted using 2019 EUCAST breakpoints. RESULTS:Ceftobiprole was active (MIC, ≤2 mg/L) against 100% and 98.9% of methicillin-susceptible Staphylococcus aureus and MRSA from 2018. Only six MRSA isolates (1.1%) were resistant to ceftobiprole and originated from four countries. Against S. pneumoniae, ceftobiprole was active (MIC, ≤0.5 mg/L) against 98.7% of isolates. Overall, 75.6% of Enterobacterales were susceptible though isolate numbers in certain countries were notably low. In addition, based on non-species related PK/PD breakpoints, 63.2% of Pseudomonas aeruginosa isolates were susceptible to ceftobiprole. CONCLUSIONS: The data for ceftobiprole for isolates from 2018 are very similar to studies performed on isolates from earlier years showing that susceptibility to ceftobiprole has remained high.